Luly Jay R. — SEC Form 4 filings
SEC reporting owner CIK 1571211. 10 Form 4 filings on record with FilingPulse; latest filed 2026-02-13.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-02-14 to 2026-02-13. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 45,000 shares, $256,050 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 9,885 shares, $108,937 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 11.
- Largest priced transaction: purchase of 45,000 shares @ $5.69 ($256,050) in ENANTA PHARMACEUTICALS INC, filed 2025-02-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | President and CEO, Director | 10 | 1 leg · 45,000 sh · $256,050 | 2 legs · 9,885 sh · $108,937 | 11 |
Form 4 filings — Luly Jay R.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-02-13 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Grant/award (A): 4,800 @ $0 · Grant/award (A): 15,200 @ $0 · Tax withholding (F): 6,155 @ $14.25 | EDGAR |
| 2025-12-05 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Sale (S): 4,743 @ $14.23 | EDGAR |
| 2025-12-03 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Tax withholding (F): 1,885 @ $14.12 | EDGAR |
| 2025-11-26 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Grant/award (A): 310,000 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Grant/award (A): 25,500 @ $0 · Tax withholding (F): 7,484 @ $5.59 | EDGAR |
| 2025-02-12 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Purchase (P): 45,000 @ $5.69 | EDGAR |
| 2024-12-10 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Sale (S): 5,142 @ $8.06 | EDGAR |
| 2024-12-03 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Tax withholding (F): 3,829 @ $8.60 | EDGAR |
| 2024-11-27 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Grant/award (A): 5,400 @ $0 · Tax withholding (F): 1,584 @ $12.41 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1571211 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →